Fujian Cancer Hospital Launches Phase 2 Clinical Trial to Treat Metastatic Colorectal Cancer

Fujian Cancer Hospital has initiated a Phase 2 clinical trial to assess the efficacy and safety of two combination chemotherapy regimens for treating metastatic colorectal cancer. The trial, launched on July 17, will randomize 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer to receive either FOLFOXIRI with Bevacizumab or FOLFOX with Cetuximab, both combined with QL1706. The study aims to determine the optimal treatment regimen for patients with this specific type of cancer.

Key Takeaways:

• The Phase 2 clinical trial is a two-arm, randomized study designed to assess the efficacy and safety of two combination chemotherapy regimens for treating metastatic colorectal cancer.
• The trial will enroll 44 patients with primary left-sided, RAS and BRAF wild-type metastatic colorectal cancer, who will be randomly assigned to two treatment groups.
• Group A will receive FOLFOXIRI with Bevacizumab, while Group B will receive FOLFOX with Cetuximab, both combined with QL1706.
• The treatment schedule for both groups involves administering the chemotherapy regimen every 2 weeks for a maximum of 9 cycles.
• After completing the initial treatment, patients may receive maintenance treatment with Capecitabine or 5-FU/LV with or without Bevacizumab.
• The trial will continue until patients experience clinical benefit, intolerable toxicity, withdrawal of informed consent, or meet other criteria for terminating treatment.

Statistics:

• 44 patients will be enrolled in the clinical trial.
• The study will randomize patients into two treatment groups (Group A and Group B).
• The maximum duration of the initial treatment is 9 cycles, every 2 weeks.
• The total duration of the trial will be 52 weeks.
• The study aims to determine the optimal treatment regimen for patients with left-sided, RAS and BRAF wild-type metastatic colorectal cancer.

Sources:

• ClinicalTrials.gov